We appreciated reading the article by Zhang et al [1] about a retrospective study of 102 mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) patients with epilepsy in which disability and outcome were assessed (median follow-up: 4 years). Administration of levetirazetam (LEV) was associated with a better outcome compared to other antiepileptic drugs (AEDs).
[1]
The study has several shortcomings requiring discussion.
The first shortcoming is that the design was retrospective and that the follow-up investigations were carried out by telephone interviews. Retrospective evaluation is dependant on the quality of the documentation and this may vary between patients. Telephone interviews cannot accurately assess the physical abilities of a patient. Additionally, the retrospective design does not allow accurately controlling the adherence to the AED medication. It is also improbable that the outcome parameter modified ranking scale may depend on the AED treatment. Since MELAS is a multisystem disease, outcome, survival, and mortality may not only depend on the AED treatment. Outcome also may strongly depend on severity and progression of myopathy and the frequency and severity of stroke-like episodes (SLEs), the hallmark of the phenotype. MELAS frequently manifests with psychiatric abnormalities, which require adequate anti-depressive, anti-anxiety, or antipsychotic medication and may strongly determine the outcome as well. Cardiac disease in MELAS has also a strong impact on the survival rate, as cardiomyopathy, heart failure, cardio-embolism, ventricular arrhythmias, and sudden cardiac death may impact prognosis and survival. Unfortunately, the paper did not mention how many of these 102 patients had myopathy, SLEs, cardiac involvement, or psychiatric disease.
A further shortcoming is that the numbers of potentially mitochondrion-toxic AEDs applied were different in the LEV and non-LEV groups.
[1] Potentially mitochondriontoxic AEDs are carbamazepine (CBZ), valproic acid (VPA), Phenobarbital, and phenytoin. In the LEV group, 10 patients were on mitochondrion-toxic AEDs.
[1] In the non-LEV group, 41 patients were on potentially mitochondrion-toxic AEDs. Four patients were even on a combination of CBZ and VPA.
[1] This significant difference implied that rather the lower mitochondrion-toxic potential of the AED treatment in the LEV group than LEV itself was responsible for the apparently better outcome in the LEV group. The outcome of MELAS may also strongly depend on the quality of seizure control. However, the article did not mention if quality of seizures control was better in either group. The outcome may also depend on the semiology and severity of seizures. The apparently better outcome in the LEV group may be attributable to a lower frequency of severe seizure types, such as generalized seizures or epileptic states. Thus, we should be informed about seizures frequencies and seizures types to assess if these parameters influenced the outcome.
Overall, this interesting study would be more meaningful if not only type of AED treatment but also seizure frequency, types of seizures, quality of seizure control, and multimorbidity were included in the calculation of mortality. It is not permissible to draw the conclusion that administration of LEV was associated with a lower mortality in MELAS.
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